Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

CORT

Corcept Therapeutics Inc

Jan 08 • 11:30AM ET

36.79

-0.21 -0.57 %

Healthcare • Biotechnology • USA • NASD

Peers: NBIX SRPT TGTX MDGL ARDX ANAB VKTX AKBA LGND PSTV

| Held by: VTI IJR VB VBK VXF SPSM IJT VIOO IWP VHT

Scroll to Statements

Index	-	P/E	42.03	EPS (ttm)	0.88	Insider Own	11.68%	Shs Outstand	105.12M	Perf Week	5.71%
Market Cap	3.87B	Forward P/E	64.84	EPS next Y	0.57	Insider Trans	-3.80%	Shs Float	92.90M	Perf Month	-55.67%
Enterprise Value	3.45B	PEG	2.20	EPS next Q	0.25	Inst Own	74.68%	Short Float	10.88%	Perf Quarter	-58.40%
Income	104.65M	P/S	5.22	EPS this Y	-28.34%	Inst Trans	-1.04%	Short Ratio	7.06	Perf Half Y	-48.91%
Sales	741.17M	P/B	6.12	EPS next Y	-35.63%	ROA	13.02%	Short Interest	10.11M	Perf YTD	5.71%
Book/sh	6.01	P/C	9.18	EPS next 5Y	29.41%	ROE	16.47%	52W High	117.33 -68.65%	Perf Year	-28.79%
Cash/sh	4.01	P/FCF	23.80	EPS past 3/5Y	11.29% 9.89%	ROIC	16.42%	52W Low	32.99 11.51%	Perf 3Y	82.39%
Dividend Est.	-	EV/EBITDA	51.22	Sales past 3/5Y	22.64% 17.11%	Gross Margin	98.19%	Volatility	10.10% 6.10%	Perf 5Y	40.63%
Dividend TTM	-	EV/Sales	4.66	EPS Y/Y TTM	-26.13%	Oper. Margin	8.85%	ATR (14)	5.02	Perf 10Y	615.73%
Dividend Ex-Date	-	Quick Ratio	3.07	Sales Y/Y TTM	17.92%	Profit Margin	14.12%	RSI (14)	21.13	Recom	1.86
Dividend Gr. 3/5Y	- -	Current Ratio	3.14	EPS Q/Q	-60.52%	SMA20	-46.58%	Beta	0.24	Target Price	91.00
Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	13.75%	SMA50	-50.24%	Rel Volume	0.73	Prev Close	37.00
Employees	500	LT Debt/Eq	0.01	Earnings	Nov 04 AMC	SMA200	-49.87%	Avg Volume	1.43M	Price	36.79
IPO	Apr 14, 2004	Option/Short	Yes / Yes	EPS/Sales Surpr.	-2.26% -6.96%	Trades		Volume	358,326	Change	-0.57%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-31-25	Downgrade	Wolfe Research	Peer Perform → Underperform	$30
Dec-16-25	Initiated	UBS	Neutral
Nov-18-25	Initiated	Wolfe Research	Peer Perform
Nov-06-23	Upgrade	Truist	Hold → Buy	$29 → $38
Apr-11-23	Initiated	SVB Securities	Market Perform	$25
Apr-04-23	Initiated	Piper Sandler	Overweight	$27
Feb-15-23	Downgrade	Jefferies	Buy → Hold	$35 → $22
Aug-01-22	Downgrade	Truist	Buy → Hold	$30
Jul-27-22	Upgrade	Jefferies	Hold → Buy	$21 → $35
Jun-27-22	Resumed	Canaccord Genuity	Buy	$30 → $34
Feb-02-22	Initiated	Canaccord Genuity	Buy	$30
Jan-28-22	Initiated	Truist	Buy	$30
Aug-05-20	Downgrade	Jefferies	Buy → Hold	$16
Sep-24-19	Initiated	Jefferies	Buy	$20
Sep-06-19	Initiated	H.C. Wainwright	Buy	$18
Feb-04-19	Downgrade	B. Riley FBR	Buy → Neutral	$22 → $12
Aug-10-18	Reiterated	Stifel	Hold	$20 → $11
May-31-18	Downgrade	Stifel	Buy → Hold	$20
Mar-09-18	Initiated	B. Riley FBR, Inc.	Buy	$30
Aug-31-17	Initiated	Stifel	Buy	$20

Show Previous Ratings

Jan-06-26 12:01PM	Corcept Therapeutics (CORT) Faces Investor Scrutiny Amid Receipt of FDA Complete Response Letter For Relacorilant, Shares Tank 50% - Hagens Berman (PR Newswire)
Jan-05-26 11:31PM	1 Healthcare Stock to Target This Week and 2 We Turn Down (StockStory) -8.51%
12:16PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
09:54AM	Corcept (CORT) Surges 9.8%: Is This an Indication of Further Gains? (Zacks)
Jan-02-26 11:17AM	The FDA Just Snubbed Corcept Therapeutics. Should You Buy the Dip in CORT Stock or Stay Far Away (Barchart) +9.77%
10:22AM	Loading…
10:22AM	Corcept Tanks on FDA's CRL to Relacorilant NDA in Hypercortisolism (Zacks)
08:50AM	Implied Volatility Surging for Corcept Stock Options (Zacks)
07:30AM	Company News for Jan 2, 2026 (Zacks)
Jan-01-26 08:10AM	FDA says it needs additional evidence of effectiveness for Corcept relacorilant (TipRanks)
Dec-31-25 06:41PM	Why Corcept Therapeutics Plummeted by 50% Today (Motley Fool) -50.42% +9.77%
05:00PM	Why Corcept (CORT) Shares Are Falling Today (StockStory)
04:34PM	Stocks Settle Lower on Tech Weakness and Higher Bond Yields (Barchart)
12:31PM	Corcept Therapeutics Shares Plunge 50% After FDA Rejects Blood Pressure Drug (Barrons.com)
10:00AM	Corcept Sinks After FDA Rejects Drug to Treat Hypertension (Bloomberg)
09:57AM	Stocks Slide on Weakness in Megacap Tech Stocks (Barchart)
08:00AM	Loading…
08:00AM	Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism (Business Wire)
Dec-30-25 06:32AM	Stock Market Today: Stocks Struggling to Finish 2025 on High Note (TheStreet) -12.06%
Dec-23-25 03:51PM	Why Corcept (CORT) Stock Is Trading Lower Today (StockStory)
Dec-21-25 08:56AM	Corcept Therapeutics (CORT): Analyst Says Shares Pricing in Growth, New Launch (Insider Monkey)
Dec-16-25 11:03PM	Corcept (CORT): Buy, Sell, or Hold Post Q3 Earnings? (StockStory) -7.08%
02:05PM	Why Corcept (CORT) Stock Is Down Today (StockStory)
Dec-11-25 07:44AM	Wall Street Firms Tout Corcept Therapeutics Incorporated (CORT) Prospects on Korlym Medication Prospects (Insider Monkey)
Dec-10-25 11:30AM	Theravance Bio (TBPH) Down 3.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Dec-07-25 10:33PM	Analysts See 70% Upside Potential in Corcept Therapeutics (CORT) Stock (Insider Monkey)
Dec-04-25 11:30AM	Corcept (CORT) Up 9.2% Since Last Earnings Report: Can It Continue? (Zacks)
Dec-01-25 11:04AM	Will Korlym Continue to Drive Corcept's Top Line in 2026? (Zacks)
Nov-26-25 02:59PM	Corcept Therapeutics Incorporated (CORT) Modifies Revenue Guidance while Banking on Cushing Syndrome Treatment for Growth (Insider Monkey)
Nov-12-25 10:34PM	Branded Pharmaceuticals Stocks Q3 Recap: Benchmarking Corcept (NASDAQ:CORT) (StockStory)
Nov-11-25 12:36AM	The 5 Most Interesting Analyst Questions From Corcept's Q3 Earnings Call (StockStory)
Nov-05-25 10:01AM	Corcept Q3 Earnings & Revenues Lag Estimates, '25 View Cut, Stock Down (Zacks) +7.81%
08:31AM	Loading…
08:31AM	CORT Q3 Deep Dive: Pharmacy Transition and Pipeline Expansion Drive Mixed Outlook (StockStory)
12:10AM	Corcept Therapeutics Inc (CORT) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst Net ... (GuruFocus.com)
Nov-04-25 06:25PM	Corcept Therapeutics (CORT) Q3 Earnings and Revenues Miss Estimates (Zacks)
06:00PM	Corcept (NASDAQ:CORT) Reports Sales Below Analyst Estimates In Q3 Earnings (StockStory)
05:20PM	Corcept: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Third Quarter Financial Results, Oncology Development Programs and Provides Corporate Update (Business Wire)
09:36AM	What Does Wall Street Think About Corcept Therapeutics (CORT)? (Insider Monkey)
Nov-02-25 10:04PM	Corcept Earnings: What To Look For From CORT (StockStory)
Oct-29-25 10:00AM	NewAmsterdam Pharma Company N.V. (NAMS) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-28-25 04:05PM	Corcept Therapeutics to Announce Third Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Oct-22-25 10:00AM	Analysts Estimate Corcept Therapeutics (CORT) to Report a Decline in Earnings: What to Look Out for (Zacks)
Oct-19-25 05:15AM	Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment (Business Wire)
Oct-17-25 09:54PM	H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) (Insider Monkey)
Oct-15-25 02:02PM	Corcept (CORT) Shares Skyrocket, What You Need To Know (StockStory) +6.50%
11:35AM	CORT Files MAA for Relacorilant in Platinum-Resistant Ovarian Cancer (Zacks)
Oct-14-25 08:00AM	Corcept Submits Marketing Authorization Application to European Medicines Agency for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Oct-10-25 11:51AM	Why Corcept (CORT) Shares Are Falling Today (StockStory) -16.30%
Oct-03-25 08:21AM	Here's What Makes Corcept Therapeutics (CORT) an Attractive Investment? (Insider Monkey)
Oct-01-25 04:01PM	Why Corcept (CORT) Stock Is Trading Up Today (StockStory)
10:40AM	Can Relacorilant Drive Corcept's Long-Term Growth Beyond Korlym? (Zacks)
Sep-29-25 07:20PM	Corcept Therapeutics Beats Q2 Estimates, Cuts Guidance and Advances NDA for New Cancer Drug (Insider Monkey)
Sep-24-25 04:06AM	FDA Accepts New Drug Application for Corcept Therapeutics's (CORT) Relacorilant (Insider Monkey)
Sep-23-25 03:25PM	Why Are Corcept (CORT) Shares Soaring Today (StockStory)
Sep-22-25 02:30PM	Corcept to Present New Late-Breaking Data From Pivotal ROSELLA Trial of Relacorilant in Platinum-Resistant Ovarian Cancer at ESMO 2025 (Business Wire)
Sep-16-25 12:02AM	Corcept (CORT): Buy, Sell, or Hold Post Q2 Earnings? (StockStory)
Sep-15-25 11:36PM	Q2 Earnings Roundup: Corcept (NASDAQ:CORT) And The Rest Of The Branded Pharmaceuticals Segment (StockStory)
02:18PM	11 fast-growing small-cap stocks that could get a boost from the Fed's next move (MarketWatch)
Sep-11-25 11:57AM	FDA Accepts Corcept's NDA for Relacorilant in Ovarian Cancer (Zacks)
03:31AM	Corcept's (CORT) Multibagger Momentum Builds on Relacorilant and Expanding Commercial Footprint (Insider Monkey)
Sep-10-25 08:00AM	FDA Files Corcept's New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Sep-02-25 09:58AM	Can Korlym Drive Corcept's Growth Through the Rest of 2025? (Zacks)
Aug-25-25 02:03PM	Corcept Shares Rise 39.6% in YTD: How Should You Play the Stock? (Zacks)
Aug-22-25 11:57PM	Canaccord Genuity Maintains a Buy on Corcept Therapeutics (CORT), Retains a $137 PT (Insider Monkey)
Aug-13-25 12:25AM	5 Must-Read Analyst Questions From Corcept's Q2 Earnings Call (StockStory)
12:00AM	CORT Q2 Deep Dive: Product Supply Constraints and Pipeline Progress Reshape Outlook (StockStory)
Aug-01-25 12:04PM	CORT's Q2 Earnings Top Mark, Revenues Lag, '25 View Cut, Stock Down (Zacks)
Jul-31-25 05:35PM	Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates (Zacks)
05:27PM	Corcept (NASDAQ:CORT) Misses Q2 Sales Targets (StockStory)
04:36PM	Corcept: Q2 Earnings Snapshot (Associated Press Finance)
04:05PM	Corcept Therapeutics Announces Second Quarter Financial Results and Provides Corporate Update (Business Wire)
Jul-29-25 11:05PM	What To Expect From Corcept's (CORT) Q2 Earnings (StockStory)
Jul-28-25 02:07AM	H.C. Wainwright Remains Bullish on Corcept Therapeutics Incorporated (CORT) (Insider Monkey)
Jul-27-25 09:58AM	Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk (Insider Monkey)
Jul-24-25 11:48PM	Corcept (CORT) Advances Ovarian Cancer Therapy with FDA Filing for Relacorilant (Insider Monkey)
04:05PM	Corcept Therapeutics to Announce Second Quarter Financial Results, Provide Corporate Update and Host Conference Call (Business Wire)
Jul-23-25 11:00AM	Corcept Advances Cancer Drug as Analysts Back Strong Growth Prospects (Insider Monkey)
Jul-17-25 07:10AM	Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last? (Zacks)
12:08AM	3 Reasons CORT is Risky and 1 Stock to Buy Instead (StockStory)
Jul-15-25 10:17AM	Corcept Seeks FDA Approval for Relacorilant in Ovarian Cancer (Zacks)
Jul-14-25 08:00AM	Corcept Submits New Drug Application for Relacorilant as a Treatment for Patients with Platinum-Resistant Ovarian Cancer (Business Wire)
Jul-06-25 04:15AM	Corcept Therapeutics (CORT) Announces Pivotal Data from Phase 3 ROSELLA Trial (Insider Monkey)
Jul-04-25 01:48AM	Corcept Therapeutics' Korlym Shows Glucose Control, Weight Reduction in Hypercortisolism, Type 2 Diabetes Patients (Insider Monkey)
Jun-30-25 06:20AM	Should Invesco S&P SmallCap Momentum ETF (XSMO) Be on Your Investing Radar? (Zacks)
Jun-27-25 08:56AM	Aurinia (AUPH) Surges 7.5%: Is This an Indication of Further Gains? (Zacks)
Jun-26-25 05:52PM	5 Insightful Analyst Questions From Corcept's Q1 Earnings Call (StockStory)
Jun-24-25 03:09PM	Corcept ALS Drug Shows Significant Survival Benefit Despite Missed Primary Endpoint (Insider Monkey)
Jun-23-25 04:30PM	Corcept Presents Data from Treatment Phase of CATALYST Trial at American Diabetes Association's 85th Scientific Sessions with Simultaneous Publication in Diabetes Care (Business Wire)
Jun-16-25 06:20AM	Should JPMorgan Diversified Return U.S. Small Cap Equity ETF (JPSE) Be on Your Investing Radar? (Zacks)
Jun-11-25 06:20AM	Is Invesco S&P SmallCap Quality ETF (XSHQ) a Strong ETF Right Now? (Zacks)
Jun-06-25 06:20AM	Should Goldman Sachs ActiveBeta U.S. Small Cap Equity ETF (GSSC) Be on Your Investing Radar? (Zacks)
Jun-05-25 11:20AM	Corcept Therapeutics Therapy Fails Primary Goal But Extends Patient Survival In Amyotrophic Lateral Sclerosis Study (Benzinga)
06:20AM	Should Invesco S&P SmallCap Quality ETF (XSHQ) Be on Your Investing Radar? (Zacks)
06:00AM	Corcept Presents Results from Phase 2 Study of Dazucorilant in Patients with Amyotrophic Lateral Sclerosis (ALS) at ENCALS 2025 Annual Meeting (Business Wire)
Jun-04-25 11:30AM	Corcept (CORT) Down 1.7% Since Last Earnings Report: Can It Rebound? (Zacks)
Jun-03-25 02:59AM	Why Corcept Therapeutics Incorporated (CORT) Crashed On Monday (Insider Monkey)
Jun-02-25 11:15AM	Corcept Presents Pivotal Clinical Data in ASCO Late-Breaker with Simultaneous Publication in The Lancet: Relacorilant Improves Progression-Free and Overall Survival in Patients with Platinum-Resistant Ovarian Cancer (Business Wire) -7.58%
May-29-25 06:11AM	New Strong Sell Stocks for May 29th (Zacks)
May-21-25 11:31PM	Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Corcept (NASDAQ:CORT) (StockStory)
May-19-25 08:04AM	CORT Q1 Earnings Call: Pharmacy Disruptions Overshadow Prescription Growth, Guidance Reaffirmed (StockStory)
May-11-25 05:17PM	Why Corcept Therapeutics (CORT) Is Among the Best Performing Healthcare Stocks to Buy Now (Insider Monkey)

Corcept Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. Singer and Joseph K. Belanoff on May 13, 1998 and is headquartered in Redwood City, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Guyer William	Officer	Jan 06 '26	Proposed Sale	34.95	20,000	699,000		Jan 06 12:04 PM
Robb Gary Charles	Chief Business Officer	Dec 24 '25	Option Exercise	3.88	145,000	562,600	158,910	Dec 29 05:58 PM
BELANOFF JOSEPH K	Chief Executive Officer	Dec 24 '25	Option Exercise	3.88	550,000	2,134,000	550,000	Dec 29 05:24 PM
Guyer William	Chief Development Officer	Dec 02 '25	Option Exercise	21.65	20,000	433,000	21,235	Dec 03 09:19 PM
Guyer William	Chief Development Officer	Dec 02 '25	Sale	80.08	20,000	1,601,526	1,235	Dec 03 09:19 PM
Maduck Sean	See Remarks	Dec 01 '25	Option Exercise	8.27	20,000	165,400	27,904	Dec 03 08:53 PM
Maduck Sean	See Remarks	Dec 01 '25	Sale	79.52	20,000	1,590,490	7,904	Dec 03 08:53 PM
Lyon Joseph Douglas	See Remarks	Dec 01 '25	Option Exercise	13.56	5,000	67,800	15,277	Dec 03 08:36 PM
Lyon Joseph Douglas	See Remarks	Dec 01 '25	Sale	79.53	5,000	397,632	10,277	Dec 03 08:36 PM
BELANOFF JOSEPH K	Chief Executive Officer	Dec 01 '25	Sale	79.77	40,000	3,190,796	2,701,370	Dec 03 08:14 PM
Guyer William	Officer	Dec 02 '25	Proposed Sale	79.78	20,000	1,595,600		Dec 02 10:34 AM
BELANOFF JOSEPH K	Officer	Dec 01 '25	Proposed Sale	79.40	40,000	3,176,000		Dec 01 02:36 PM
Maduck Sean	Officer	Dec 01 '25	Proposed Sale	79.40	20,000	1,588,000		Dec 01 02:00 PM
Lyon Joseph Douglas	Officer	Dec 01 '25	Proposed Sale	79.40	5,000	397,000		Dec 01 01:50 PM
Guyer William	Chief Development Officer	Nov 25 '25	Sale	80.90	4,500	364,070	787	Nov 26 05:22 PM
Guyer William	Officer	Nov 25 '25	Proposed Sale	80.90	4,500	364,070		Nov 25 04:46 PM
Guyer William	Chief Development Officer	Nov 05 '25	Option Exercise	21.65	20,000	433,000	25,287	Nov 07 05:10 PM
Guyer William	Chief Development Officer	Nov 05 '25	Sale	75.36	20,000	1,507,122	5,287	Nov 07 05:10 PM
Lyon Joseph Douglas	See Remarks	Nov 03 '25	Option Exercise	13.56	5,000	67,800	15,277	Nov 05 07:59 PM
Lyon Joseph Douglas	See Remarks	Nov 03 '25	Sale	73.65	5,000	368,244	10,277	Nov 05 07:59 PM
BELANOFF JOSEPH K	Chief Executive Officer	Nov 05 '25	Sale	74.77	28,782	2,152,105	2,741,370	Nov 05 07:57 PM
BELANOFF JOSEPH K	Chief Executive Officer	Nov 03 '25	Sale	74.08	11,218	831,014	2,770,152	Nov 05 07:57 PM
Maduck Sean	See Remarks	Nov 03 '25	Option Exercise	8.27	20,000	165,400	27,904	Nov 05 07:56 PM
Maduck Sean	See Remarks	Nov 03 '25	Sale	73.99	20,000	1,479,816	7,904	Nov 05 07:56 PM
Guyer William	Officer	Nov 05 '25	Proposed Sale	71.10	20,000	1,422,000		Nov 05 10:12 AM
BELANOFF JOSEPH K	Officer	Nov 03 '25	Proposed Sale	73.47	40,000	2,938,800		Nov 03 04:06 PM
Lyon Joseph Douglas	Officer	Nov 03 '25	Proposed Sale	73.47	5,000	367,350		Nov 03 03:31 PM
Maduck Sean	Officer	Nov 03 '25	Proposed Sale	73.47	20,000	1,469,400		Nov 03 03:25 PM
Swisher Daniel N JR	Director	Oct 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Oct 15 06:31 PM
Swisher Daniel N JR	Director	Oct 10 '25	Sale	87.54	2,200	192,588	0	Oct 15 06:31 PM
Swisher Daniel N JR	Director	Oct 10 '25	Proposed Sale	87.54	2,200	192,588		Oct 10 10:44 AM
Guyer William	Chief Development Officer	Oct 07 '25	Option Exercise	21.65	20,000	433,000	25,287	Oct 09 05:51 PM
Guyer William	Chief Development Officer	Oct 07 '25	Sale	89.94	20,000	1,798,782	5,287	Oct 09 05:51 PM
Guyer William	Officer	Oct 07 '25	Proposed Sale	89.85	20,000	1,797,000		Oct 07 01:51 PM
BELANOFF JOSEPH K	Chief Executive Officer	Oct 01 '25	Sale	85.08	40,000	3,403,253	2,781,370	Oct 03 05:24 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '25	Option Exercise	13.56	5,000	67,800	15,277	Oct 03 05:17 PM
Lyon Joseph Douglas	See Remarks	Oct 01 '25	Sale	84.75	5,000	423,766	10,277	Oct 03 05:17 PM
Maduck Sean	See Remarks	Oct 01 '25	Option Exercise	7.95	20,000	159,005	27,904	Oct 03 05:15 PM
Maduck Sean	See Remarks	Oct 01 '25	Sale	85.06	20,000	1,701,232	7,904	Oct 03 05:15 PM
BELANOFF JOSEPH K	Officer	Oct 01 '25	Proposed Sale	83.11	40,000	3,324,400		Oct 01 03:34 PM
Maduck Sean	Officer	Oct 01 '25	Proposed Sale	83.11	20,000	1,662,200		Oct 01 01:54 PM
Lyon Joseph Douglas	Officer	Oct 01 '25	Proposed Sale	83.11	5,000	415,550		Oct 01 01:42 PM
Swisher Daniel N JR	Director	Sep 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Sale	72.45	2,200	159,390	0	Sep 11 08:38 PM
Swisher Daniel N JR	Director	Sep 10 '25	Proposed Sale	72.45	2,200	159,390		Sep 10 09:50 AM
Cannon Gillian	Director	Sep 04 '25	Option Exercise	22.99	11,000	252,890	11,000	Sep 08 08:20 PM
Guyer William	Chief Development Officer	Sep 02 '25	Option Exercise	21.65	20,000	433,000	25,487	Sep 04 07:59 PM
Guyer William	Chief Development Officer	Sep 02 '25	Sale	70.49	20,000	1,409,848	5,487	Sep 04 07:59 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Option Exercise	13.56	5,000	67,800	15,066	Sep 04 07:56 PM
Lyon Joseph Douglas	See Remarks	Sep 02 '25	Sale	70.25	5,000	351,247	10,066	Sep 04 07:56 PM
Maduck Sean	See Remarks	Sep 02 '25	Option Exercise	5.05	20,000	101,000	27,681	Sep 04 07:54 PM
Maduck Sean	See Remarks	Sep 02 '25	Sale	70.49	20,000	1,409,828	7,681	Sep 04 07:54 PM
BELANOFF JOSEPH K	Chief Executive Officer	Sep 02 '25	Sale	70.53	40,000	2,821,033	2,821,370	Sep 04 07:54 PM
Guyer William	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:31 PM
Maduck Sean	Officer	Sep 02 '25	Proposed Sale	69.72	20,000	1,394,400		Sep 02 04:23 PM
Lyon Joseph Douglas	Officer	Sep 02 '25	Proposed Sale	69.72	5,000	348,600		Sep 02 04:16 PM
BELANOFF JOSEPH K	Officer	Sep 02 '25	Proposed Sale	69.72	40,000	2,788,800		Sep 02 04:09 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Option Exercise	3.88	5,000	19,400	18,364	Aug 26 06:56 PM
Robb Gary Charles	Chief Business Officer	Aug 22 '25	Sale	71.27	2,326	165,774	16,038	Aug 26 06:56 PM
Robb Gary Charles	Officer	Aug 22 '25	Proposed Sale	71.27	2,326	165,774		Aug 22 10:58 AM
Swisher Daniel N JR	Director	Aug 11 '25	Option Exercise	14.08	2,200	30,976	2,200	Aug 12 07:22 PM
Swisher Daniel N JR	Director	Aug 11 '25	Sale	72.30	2,200	159,060	0	Aug 12 07:22 PM
Guyer William	Chief Development Officer	Aug 08 '25	Option Exercise	21.65	35,007	757,902	40,494	Aug 12 07:19 PM
Guyer William	Chief Development Officer	Aug 08 '25	Sale	71.77	35,007	2,512,452	5,487	Aug 12 07:19 PM
Swisher Daniel N JR	Director	Aug 11 '25	Proposed Sale	72.30	2,200	159,060		Aug 11 10:20 AM
Guyer William	Chief Development Officer	Aug 05 '25	Option Exercise	21.65	14	303	5,501	Aug 07 07:17 PM
Guyer William	Chief Development Officer	Aug 05 '25	Sale	71.77	14	1,005	5,487	Aug 07 07:17 PM
Maduck Sean	See Remarks	Aug 01 '25	Option Exercise	5.05	35,007	176,785	42,688	Aug 05 06:51 PM
Maduck Sean	See Remarks	Aug 01 '25	Sale	67.79	35,007	2,373,237	7,681	Aug 05 06:51 PM
BELANOFF JOSEPH K	Chief Executive Officer	Aug 01 '25	Sale	68.53	40,000	2,741,207	2,861,370	Aug 05 06:51 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Option Exercise	13.56	5,823	78,960	15,889	Aug 05 06:47 PM
Lyon Joseph Douglas	See Remarks	Aug 01 '25	Sale	67.51	5,823	393,128	10,066	Aug 05 06:47 PM
Guyer William	Officer	Aug 05 '25	Proposed Sale	71.77	20,000	1,435,400		Aug 05 01:05 PM
Lyon Joseph Douglas	Officer	Aug 01 '25	Proposed Sale	67.17	5,000	335,850		Aug 01 11:25 AM
Maduck Sean	Officer	Aug 01 '25	Proposed Sale	67.15	20,000	1,343,000		Aug 01 11:11 AM
BELANOFF JOSEPH K	Officer	Aug 01 '25	Proposed Sale	67.17	615	41,310		Aug 01 11:00 AM
Maduck Sean	See Remarks	Jul 17 '25	Option Exercise	5.05	4,315	21,791	22,020	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Option Exercise	5.05	473	2,389	18,178	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 17 '25	Sale	73.48	4,315	317,054	17,705	Jul 21 07:14 PM
Maduck Sean	See Remarks	Jul 18 '25	Sale	73.44	473	34,737	17,705	Jul 21 07:14 PM
BELANOFF JOSEPH K	Chief Executive Officer	Jul 17 '25	Sale	73.69	615	45,318	2,901,370	Jul 21 07:11 PM
Lyon Joseph Douglas	See Remarks	Jul 17 '25	Option Exercise	13.56	3,877	52,572	13,943	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 18 '25	Option Exercise	13.56	200	2,712	10,266	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 17 '25	Sale	73.48	3,877	284,864	10,066	Jul 21 07:10 PM
Lyon Joseph Douglas	See Remarks	Jul 18 '25	Sale	73.40	200	14,680	10,066	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 17 '25	Option Exercise	21.65	4,379	94,805	9,866	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 18 '25	Option Exercise	21.65	500	10,825	5,987	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 17 '25	Sale	73.48	4,379	321,774	5,487	Jul 21 07:10 PM
Guyer William	Chief Development Officer	Jul 18 '25	Sale	73.44	500	36,721	5,487	Jul 21 07:10 PM
BELANOFF JOSEPH K	Officer	Jul 17 '25	Proposed Sale	72.85	40,000	2,914,000		Jul 17 04:00 PM
Swisher Daniel N JR	Director	Jul 10 '25	Option Exercise	14.08	2,200	30,976	2,200	Jul 14 04:36 PM
Swisher Daniel N JR	Director	Jul 10 '25	Sale	71.08	2,200	156,376	0	Jul 14 04:36 PM
Swisher Daniel N JR	Director	Jul 10 '25	Proposed Sale	71.08	2,200	156,376		Jul 10 12:21 PM
Guyer William	Chief Development Officer	Jul 01 '25	Option Exercise	21.65	100	2,165	5,587	Jul 03 08:39 PM
Guyer William	Chief Development Officer	Jul 01 '25	Sale	73.50	100	7,350	5,487	Jul 03 08:39 PM
Lyon Joseph Douglas	See Remarks	Jul 01 '25	Option Exercise	13.56	100	1,356	10,166	Jul 03 08:36 PM
Lyon Joseph Douglas	See Remarks	Jul 01 '25	Sale	73.50	100	7,350	10,066	Jul 03 08:36 PM
Maduck Sean	See Remarks	Jul 01 '25	Option Exercise	5.05	205	1,035	17,910	Jul 03 08:35 PM
Maduck Sean	See Remarks	Jul 01 '25	Sale	73.45	205	15,058	17,705	Jul 03 08:35 PM
Maduck Sean	Officer	Jul 01 '25	Proposed Sale	73.40	20,000	1,468,000		Jul 01 02:09 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CORT

Corcept Therapeutics Inc

Upgrade your FINVIZ experience